Diasome Pharmaceuticals is a clinical stage biopharmaceutical company focused on the clinical and commercial development of breakthrough therapies for diabetes and obesity. Based on more than thirty years of research and development in the fields of cell receptor targeting, insulin formulation, and hepatic (liver) glucose metabolism, the company's pipeline includes novel, proprietary liver targeted insulins for both Type 1 and Type 2 diabetes patients that are currently being tested in multiple human clinical trials. In addition, Diasome is developing a first-in-class oral compound for the Type 2 diabetes population that is based upon new insights into normal glucose metabolism and a novel mechanism of action.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/06/17 | $30,000,000 |
Black Beret Life Sciences JDRF T1D Fund McDonald Partners Medicxi  | undisclosed |
